Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...
H.C. Wainwright raised the firm’s price target on Viking Therapeutics (VKTX) to $102 from $90 and keeps a Buy rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback